Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.